Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Blood

Volumn 127, Issue 7, 2016, Pages 938-947

  Kanate, Abraham S ^a   Mussetti, Alberto ^b   Kharfan Dabaja, Mohamed A ^c   Ahn, Kwang W ^d,e   Digilio, Alyssa ^d   Beitinjaneh, Amer ^f   Chhabra, Saurabh ^g   Fenske, Timothy S ^h   Freytes, Cesar ⁱ   Gale, Robert Peter ^j   Ganguly, Siddhartha ^k   Hertzberg, Mark ^l   Klyuchnikov, Evgeny ^m   Lazarus, Hillard M ⁿ   Olsson, Richard ^o,p   Perales, Miguel Angel ^q   Rezvani, Andrew ^r   Riches, Marcie ^s   Saad, Ayman ^t   Slavin, Shimon ^u   Smith, Sonali M ^v   Sureda, Anna ^w   Yared, Jean ^x   Ciurea, Stefan ^y   Armand, Philippe ^z   Salit, Rachel ^aa   Bolaños Meade, Javier ^ab   Hamadani, Mehdi ^d   more..

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^l PRINCE OF WALES HOSPITAL   (Australia)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ Seidman Cancer Center   (United States)

^o KAROLINSKA INSTITUTE   (Sweden)

^p UPPSALA UNIVERSITY   (Sweden)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^t Heerskink School of Medicine   (United States)

^u International Center for Cell Therapy and Cancer Immunotherapy   (Israel)

^v SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^w HOSPITAL DURAN I REYNALS   (Spain)

^x UNIVERSITY OF MARYLAND   (United States)

^y UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^z DANA FARBER CANCER INSTITUTE   (United States)

^aa USA   (United States)

^ab JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; FOLLOW UP; HAPLOIDENTICAL RELATED DONOR TRANSPLANTATION; HAPLOIDY; HLA MATCHED UNRELATED DONOR TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RECIPIENT; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; UNRELATED DONORS; WHOLE BODY RADIATION; ADOLESCENT; ALLOGRAFT; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

EID: 84959378642     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-671834     Document Type: Article

References (36)

1. Appelbaum FR. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program. 2008;2008(1):412-417.
2. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4): 339-348.
3. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: The first 25 years and beyond. Blood. 2013;122(4):491-498.
4. Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61(5):738-745.
5. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation. 2005;79(10): 1351-1357.
6. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
7. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339(17):1186-1193.
8. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948-3955.
9. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073.
10. Wang Y, Liu DH, Liu KY, et al. Long-term followup of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013; 119(5):978-985.
11. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-386.
12. Brunstein CG, Fuchs EJ, Carter SL, et al; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282-288.
13. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12): 1835-1844.
14. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456-3464.
15. Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211157.
16. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18(12): 1859-1866.
17. Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573-1579.
18. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-1316.
19. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
20. Castagna L, Bramanti S, Furst S, et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49(12):1475-1480.
21. Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4): 602-606.
22. Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and posttransplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49(2): 190-194.
23. Kanakry JA, Gocke CD, Bolaños-Meade J, et al. Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors. Biol Blood Marrow Transplant. 2015;21(12): 2115-2122.
24. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-1633.
25. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-3671.
26. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217.
28. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
29. Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011;101(1): 87-93.
30. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995;1(2):145-156, 159.
31. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024-3031.
32. Bachanova V, Burns LJ, Ahn KW, et al; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of pretransplantation (18)F-fluorodeoxy glucosepositron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(9):1605-1611.
33. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25): 6963-6970.
34. Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Hematology Am Soc Hematol Educ Program. 2012;2012(1): 251-264.
35. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versushost disease without improved survival. Biol Blood Marrow Transplant. 2007;13(12):1461-1468.
36. Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367(16):1487-1496.